Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats

被引:64
作者
Hashimoto, Y [1 ]
Sasa, H [1 ]
Shimomura, M [1 ]
Inui, K [1 ]
机构
[1] Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan
关键词
tacrolimus; bioavailability; metabolism; intestine; pharmacokinetics;
D O I
10.1023/A:1011967519752
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Tacrolimus, an immunosuppressive agent, has poor and variable bioavailability following oral administration in clinical use. We investigated the contribution of intestinal metabolism to the first pass effect of tacrolimus in rats. Methods. Tacrolimus was administered intravenously, intraportally or intraintestinally to rats. Blood samples were collected over a 240-min period, and blood tacrolimus concentrations were measured. The extraction ratios of tacrolimus in the intestine and liver were investigated. In addition, the metabolism of tacrolimus in the everted sacs of the small intestine was examined. Results. The rate of absorption of tacrolimus in the intestine was rapid, and tacrolimus was almost completely absorbed after intestinal administration. The bioavailability of tacrolimus was about 40% and 25% after intraportal and intraintestinal administration, respectively, indicating that tacrolimus is metabolized in both the intestine and the liver. In addition, tacrolimus was significantly metabolized in the everted sacs of the rat intestine. Conclusions. The present study suggested that the metabolism of tacrolimus in the intestine contributes to its extensive and variable first pass metabolism following the oral administration.
引用
收藏
页码:1609 / 1613
页数:5
相关论文
共 16 条
  • [1] BEAL SL, 1992, NONMEM USERS GUIDE
  • [2] Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
    Floren, LC
    Bekersky, I
    Benet, LZ
    Mekki, Q
    Dressler, D
    Lee, JW
    Roberts, JP
    Hebert, MF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) : 41 - 49
  • [3] Fromm MF, 1996, HEPATOLOGY, V24, P796
  • [4] THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE
    GOMEZ, DY
    WACHER, VJ
    TOMLANOVICH, SJ
    HEBERT, MF
    BENET, LZ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) : 15 - 19
  • [5] GRENIER FC, 1991, TRANSPLANT P, V23, P2748
  • [6] Holtbecker N, 1997, DRUG METAB DISPOS, V25, P1110
  • [7] CYCLOSPORINE METABOLISM BY P450IIIA IN RAT ENTEROCYTES - ANOTHER DETERMINANT OF ORAL BIOAVAILABILITY
    KOLARS, JC
    STETSON, PL
    RUSH, BD
    RUWART, MJ
    SCHMIEDLINREN, P
    DUELL, EA
    VOORHEES, JJ
    WATKINS, PB
    [J]. TRANSPLANTATION, 1992, 53 (03) : 596 - 602
  • [8] Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber
    Lampen, A
    Christians, U
    Gonschior, AK
    Bader, A
    Hackbarth, I
    vonEngelhardt, W
    Sewing, KF
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (08) : 1730 - 1734
  • [9] Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
    Lown, KS
    Mayo, RR
    Leichtman, AB
    Hsiao, HL
    Turgeon, DK
    SchmiedlinRen, P
    Brown, MB
    Guo, WS
    Rossi, SJ
    Benet, LZ
    Watkins, PB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) : 248 - 260
  • [10] SASA H, IN PRESS BIOL PHARM